Developer docs
API playgroundTry for free, no card

Search company profiles

AeroRx Therapeutics

Full company profile

uuid0000br2

Namestring
AeroRx Therapeutics
Legal namestring
AeroRx Therapeutics, Inc.
Websiteurl
aerorxtx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic obstructive pulmonary disease (COPD). Founded in 2022 and headquartered at the Avalon BioVentures Accelerator in La Jolla, California, the company focuses on moderate-to-severe COPD patients who are underserved by handheld inhaler-based therapies due to dexterity limitations, advanced disease, or suboptimal response to inhaled bronchodilators.

The company's lead asset, AERO-007, is a nebulized fixed-dose combination of indacaterol (a long-acting beta2 agonist, LABA) and glycopyrrolate (a long-acting muscarinic antagonist, LAMA), positioned as the first nebulized LABA+LAMA in clinical development. The product is delivered via a 510(k)-cleared standard jet nebulizer (LC Sprint) and is being pursued as a once-daily first-line maintenance therapy. In July 2025, AeroRx reported positive topline Phase 2a data demonstrating placebo-adjusted FEV1 AUC0-24h of 251 mL and 262 mL at the two dose levels (p<0.001), with data presented at the ATS 2026 International Conference. A second candidate, AERO-111, is a nebulized LABA/LAMA/ICS triple combination in IND-enabling stage for patients who escalate beyond dual bronchodilation. Both programs leverage the FDA 505(b)(2) regulatory pathway using approved active pharmaceutical ingredients.

AeroRx is pre-revenue and funds operations through equity capital. In October 2025, the company closed a $21 million Series A led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments, to fund Phase 2b dose-optimization and NDA preparation. Future revenue is expected from prescription pharmaceutical product sales through specialty pharmacies, healthcare systems, and durable medical equipment suppliers, contingent on NDA approval. The leadership team is led by co-founder and CEO Ahmet Tutuncu, MD, PhD, whose prior respiratory development work resulted in three successful NDAs/MAAs (Flutiform, Pulmicort HFA, Lonhala Magnair).

Short descriptiontext

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized LABA/LAMA (AERO-007) and LABA/LAMA/ICS (AERO-111) combination therapies for moderate-to-severe COPD patients underserved by handheld inhalers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nebulized COPD therapy, respiratory combination drugs, inhaled bronchodilator treatments, clinical-stage biopharmaceutical, pulmonary disease medications
Industry1 code
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
Product category
COPD Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through sales of prescription nebulized COPD therapies following successful clinical development, regulatory approval (NDA), and commercialization.

aerorxtx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized fixed-dose combination therapies for moderate-to-severe COPD. Its lead candidate AERO-007 combines indacaterol (LABA) and glycopyrrolate (LAMA) in a proprietary solution formulation for delivery via a standard 510(k)-cleared jet nebulizer, while AERO-111 extends the approach to a nebulized LABA+LAMA+ICS triple combination.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Placebo-adjusted FEV1 AUC0-24h of 251 mL (100/50 μg dose) and 262 mL (200/100 μg dose), both p<0.001
+3 more records
Product overview1 text field

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases. The company operates a portfolio approach with two lead product candidates: AERO-007 (Phase 2), a nebulized LABA/LAMA fixed-dose combination of indacaterol and glycopyrrolate, represents the first nebulized dual bronchodilator in development as first-line COPD maintenance therapy; and AERO-111 (IND-enabling), a nebulized LABA/LAMA/ICS triple combination targeting patients who escalate beyond dual bronchodilators. Both products are delivered via standard 510(k)-cleared jet nebulizers, addressing the treatment gap for COPD patients who are underserved by handheld inhalers.

Product and service2 records
1AERO-007
CategoryCOPD Therapeutics
Description

Proprietary nebulized LABA/LAMA fixed-dose combination bronchodilator (indacaterol and glycopyrrolate) for moderate-to-severe COPD, delivered via a standard jet nebulizer. First nebulized LABA+LAMA combination in clinical development, positioned as once-daily first-line maintenance therapy for moderate-to-severe COPD patients underserved by handheld inhalers.

2AERO-111
CategoryCOPD Therapeutics
Description

Nebulized LABA/LAMA/ICS triple combination therapy for COPD currently in IND-enabling stage, designed for COPD patients who escalate beyond dual bronchodilators and require anti-inflammatory therapy in addition to bronchodilation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Theravance developed YUPELRI (revefenacin), an FDA-approved nebulized LAMA for COPD, commercialized with Viatris. Most direct U.S. peer in nebulized COPD maintenance therapy, validating the commercial pathway AeroRx is pursuing.

TypeDirect peer
Description

Markets Lonhala Magnair, an FDA-approved nebulized glycopyrrolate (LAMA) for COPD, acquired from Elevation Pharma where AeroRx's CEO was co-founder/CMO. Closest direct competitor in the nebulized COPD maintenance segment.

TypeBroad incumbent
Description

Co-promotes YUPELRI with Theravance and has a broad respiratory and specialty portfolio. A likely strategic acquirer or commercial partner for an approved nebulized COPD asset like AERO-007.

TypeBroad incumbent
Description

Acquired Patara Pharma (founded by AeroRx CEO) and develops inhaled therapies for respiratory diseases including COPD. Direct strategic linkage through the CEO and an indicator of the typical acquirer profile for a company at AeroRx's stage.

TypeBroad incumbent
Description

Markets Trelegy Ellipta (LABA/LAMA/ICS) and Anoro Ellipta (LABA/LAMA) for COPD, the dominant dual/triple combination franchises. Most likely large-cap competitor that could develop a nebulized version of its combinations.

TypeBroad incumbent
Description

Markets Breztri Aerosphere (LABA/LAMA/ICS) and Bevespi (LABA/LAMA) for COPD. Major respiratory incumbent with the resources and franchise to compete in or acquire nebulized COPD assets.

7Boehringer Ingelheim
TypeBroad incumbent
Description

Markets Spiriva (tiotropium) and Stiolto Respimat (LABA/LAMA) for COPD, the long-standing category leader in long-acting bronchodilators. Strategic competitor/partner for any nebulized COPD franchise.

TypeBroad incumbent
Description

Markets ProAir RespiClick and has a significant respiratory generics and device portfolio, including nebulized products. Likely strategic competitor or commercial partner in the nebulized COPD space.

TypeEmerging player
Description

Clinical-stage company developing inhaled therapies for respiratory diseases using proprietary iSPERSE dry powder technology. Comparable small-cap respiratory biotech peer in inhaled/nebulized drug delivery, though focused on different formulations.

TypeEmerging player
Description

Clinical-stage biopharma developing iSPERSE-based inhaled therapies for respiratory infections, with overlap in the inhaled respiratory therapy space. Emerging comparable in the small-cap nebulized/inhaled therapeutic category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AeroRx Therapeutics

COPD Therapeuticsaerorxtx.com

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized LABA/LAMA (AERO-007) and LABA/LAMA/ICS (AERO-111) combination therapies for moderate-to-severe COPD patients underserved by handheld inhalers.

What AeroRx Therapeutics does

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic obstructive pulmonary disease (COPD). Founded in 2022 and headquartered at the Avalon BioVentures Accelerator in La Jolla, California, the company focuses on moderate-to-severe COPD patients who are underserved by handheld inhaler-based therapies due to dexterity limitations, advanced disease, or suboptimal response to inhaled bronchodilators.

The company's lead asset, AERO-007, is a nebulized fixed-dose combination of indacaterol (a long-acting beta2 agonist, LABA) and glycopyrrolate (a long-acting muscarinic antagonist, LAMA), positioned as the first nebulized LABA+LAMA in clinical development. The product is delivered via a 510(k)-cleared standard jet nebulizer (LC Sprint) and is being pursued as a once-daily first-line maintenance therapy. In July 2025, AeroRx reported positive topline Phase 2a data demonstrating placebo-adjusted FEV1 AUC0-24h of 251 mL and 262 mL at the two dose levels (p<0.001), with data presented at the ATS 2026 International Conference. A second candidate, AERO-111, is a nebulized LABA/LAMA/ICS triple combination in IND-enabling stage for patients who escalate beyond dual bronchodilation. Both programs leverage the FDA 505(b)(2) regulatory pathway using approved active pharmaceutical ingredients.

AeroRx is pre-revenue and funds operations through equity capital. In October 2025, the company closed a $21 million Series A led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments, to fund Phase 2b dose-optimization and NDA preparation. Future revenue is expected from prescription pharmaceutical product sales through specialty pharmacies, healthcare systems, and durable medical equipment suppliers, contingent on NDA approval. The leadership team is led by co-founder and CEO Ahmet Tutuncu, MD, PhD, whose prior respiratory development work resulted in three successful NDAs/MAAs (Flutiform, Pulmicort HFA, Lonhala Magnair).

AeroRx Therapeutics firmographics

Firmographics
Name
AeroRx Therapeutics
Legal name
AeroRx Therapeutics, Inc.
Website
https://aerorxtx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized LABA/LAMA (AERO-007) and LABA/LAMA/ICS (AERO-111) combination therapies for moderate-to-severe COPD patients underserved by handheld inhalers.
Ownership category
akta.pro rank

AeroRx Therapeutics industry classification

Industry
Product category
COPD Therapeutics
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Nebulized COPD therapy
  • Respiratory combination drugs
  • Inhaled bronchodilator treatments
  • Clinical-stage biopharmaceutical
  • Pulmonary disease medications

Where AeroRx Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AeroRx Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through sales of prescription nebulized COPD therapies following successful clinical development, regulatory approval (NDA), and commercialization.

Go-to-market motion1 record

Marketing channels3 records

AeroRx Therapeutics product offering

Product offering

Core offering

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized fixed-dose combination therapies for moderate-to-severe COPD. Its lead candidate AERO-007 combines indacaterol (LABA) and glycopyrrolate (LAMA) in a proprietary solution formulation for delivery via a standard 510(k)-cleared jet nebulizer, while AERO-111 extends the approach to a nebulized LABA+LAMA+ICS triple combination.

Product overview

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases. The company operates a portfolio approach with two lead product candidates: AERO-007 (Phase 2), a nebulized LABA/LAMA fixed-dose combination of indacaterol and glycopyrrolate, represents the first nebulized dual bronchodilator in development as first-line COPD maintenance therapy; and AERO-111 (IND-enabling), a nebulized LABA/LAMA/ICS triple combination targeting patients who escalate beyond dual bronchodilators. Both products are delivered via standard 510(k)-cleared jet nebulizers, addressing the treatment gap for COPD patients who are underserved by handheld inhalers.

Differentiator

Problem solved

Functional benefit

Products and services

  • AERO-007 Proprietary nebulized LABA/LAMA fixed-dose combination bronchodilator (indacaterol and glycopyrrolate) for moderate-to-severe COPD, delivered via a standard jet nebulizer. First nebulized LABA+LAMA combination in clinical development, positioned as once-daily first-line maintenance therapy for moderate-to-severe COPD patients underserved by handheld inhalers.
  • AERO-111 Nebulized LABA/LAMA/ICS triple combination therapy for COPD currently in IND-enabling stage, designed for COPD patients who escalate beyond dual bronchodilators and require anti-inflammatory therapy in addition to bronchodilation.

Quantifiable outcome

  • Placebo-adjusted FEV1 AUC0-24h of 251 mL (100/50 μg dose) and 262 mL (200/100 μg dose), both p<0.001
  • +3 more outcomes

Companies that use AeroRx Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

AeroRx Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

AeroRx Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

AeroRx Therapeutics competitors and assessment

Company assessment

Direct peers

  • Theravance Biopharma: Theravance developed YUPELRI (revefenacin), an FDA-approved nebulized LAMA for COPD, commercialized with Viatris. Most direct U.S. peer in nebulized COPD maintenance therapy, validating the commercial pathway AeroRx is pursuing.
  • Sunovion Pharmaceuticals: Markets Lonhala Magnair, an FDA-approved nebulized glycopyrrolate (LAMA) for COPD, acquired from Elevation Pharma where AeroRx's CEO was co-founder/CMO. Closest direct competitor in the nebulized COPD maintenance segment.

Broad incumbents

  • Viatris: Co-promotes YUPELRI with Theravance and has a broad respiratory and specialty portfolio. A likely strategic acquirer or commercial partner for an approved nebulized COPD asset like AERO-007.
  • Respivant Sciences (Roivant): Acquired Patara Pharma (founded by AeroRx CEO) and develops inhaled therapies for respiratory diseases including COPD. Direct strategic linkage through the CEO and an indicator of the typical acquirer profile for a company at AeroRx's stage.
  • GSK: Markets Trelegy Ellipta (LABA/LAMA/ICS) and Anoro Ellipta (LABA/LAMA) for COPD, the dominant dual/triple combination franchises. Most likely large-cap competitor that could develop a nebulized version of its combinations.
  • AstraZeneca: Markets Breztri Aerosphere (LABA/LAMA/ICS) and Bevespi (LABA/LAMA) for COPD. Major respiratory incumbent with the resources and franchise to compete in or acquire nebulized COPD assets.
  • Boehringer Ingelheim: Markets Spiriva (tiotropium) and Stiolto Respimat (LABA/LAMA) for COPD, the long-standing category leader in long-acting bronchodilators. Strategic competitor/partner for any nebulized COPD franchise.
  • Teva Pharmaceutical: Markets ProAir RespiClick and has a significant respiratory generics and device portfolio, including nebulized products. Likely strategic competitor or commercial partner in the nebulized COPD space.

Emerging players

  • Pulmatrix: Clinical-stage company developing inhaled therapies for respiratory diseases using proprietary iSPERSE dry powder technology. Comparable small-cap respiratory biotech peer in inhaled/nebulized drug delivery, though focused on different formulations.
  • Inhalon Biopharma: Clinical-stage biopharma developing iSPERSE-based inhaled therapies for respiratory infections, with overlap in the inhaled respiratory therapy space. Emerging comparable in the small-cap nebulized/inhaled therapeutic category.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights7 records

Customer concentration

AeroRx Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AeroRx Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

AeroRx Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AeroRx Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AeroRx Therapeutics

What does AeroRx Therapeutics do?

AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary nebulized fixed-dose combination therapies for moderate-to-severe COPD. Its lead candidate AERO-007 combines indacaterol (LABA) and glycopyrrolate (LAMA) in a proprietary solution formulation for delivery via a standard 510(k)-cleared jet nebulizer, while AERO-111 extends the approach to a nebulized LABA+LAMA+ICS triple combination.

Is AeroRx Therapeutics a public or private company?

AeroRx Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was AeroRx Therapeutics founded?

AeroRx Therapeutics was founded in 2023. It employs 1 to 10 people.

Where is AeroRx Therapeutics based?

AeroRx Therapeutics is headquartered in San Diego, United States, in the North America region.

How does AeroRx Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are AeroRx Therapeutics's main competitors?

Direct peers on record are Theravance Biopharma and Sunovion Pharmaceuticals. Broad incumbents are Viatris, Respivant Sciences (Roivant), GSK, AstraZeneca, Boehringer Ingelheim and Teva Pharmaceutical. Emerging players are Pulmatrix and Inhalon Biopharma.

Does AeroRx Therapeutics have an API?

No public API is recorded for AeroRx Therapeutics.

What industry is AeroRx Therapeutics in?

AeroRx Therapeutics's product category is COPD Therapeutics. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAeroRx Therapeutics Presents Positive Phase 2a Data for Inhaled AERO-007, the First Potential Nebulized LABA+LAMA Fixed-Dose Combination in Development for COPDAeroRx Therapeutics presented positive Phase 2a data for AERO-007, the first nebulized LABA+LAMA fixed-dose combination in clinical development for COPD, at the ATS 2026 International Conference on May 17, 2026. The randomized, double-blind, placebo-controlled study in 16 moderate-to-severe COPD patients demonstrated statistically significant bronchodilation sustained over 24 hours at both dose levels, with favorable tolerability and no adverse events leading to discontinuation. The company stated the data support advancing AERO-007 as a potential once-daily first-line maintenance therapy for COPD patients who require or prefer nebulized treatment.BioSpaceAeroRx Therapeutics Presents Positive Phase 2a Data for Inhaled AERO-007, the First Potential Nebulized LABA+LAMA Fixed-Dose Combination in Development for COPDAeroRx Therapeutics presented positive Phase 2a data for inhaled AERO-007, a nebulized LABA+LAMA fixed-dose combination, at ATS 2026. The study in 16 COPD patients showed sustained bronchodilation over 24 hours and a favorable tolerability profile, supporting continued development as a potential first-line maintenance therapy.GlobeNewswireChronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightDelveInsight released a comprehensive report finding that over 65 companies are developing 75+ pipeline drugs for chronic obstructive pulmonary disease, with approximately 12 drugs in late-stage development and the treatment landscape shifting toward targeted biologics and anti-inflammatory therapies. Key recent developments include AstraZeneca's tozorakimab meeting primary endpoints in both OBERON and TITANIA Phase III trials (March 2026), Expedition Therapeutics securing $165 million Series A financing for its COPD candidate EXPD-101 (October 2025), and AeroRx Therapeutics reporting positive Phase IIa proof-of-concept results for AERO-007 (July 2025). The report identifies emerging mechanisms of action including thymic stromal lymphopoietin inhibitors, interleukin-33 inhibitors, and IRAK4 inhibitors as promising therapeutic targets.Pulse 2.0AeroRx Therapeutics: $21 Million Series A Closed For Advancing Inhaled AERO-007 For COPD Into Late-Stage DevelopmentAeroRx Therapeutics, a clinical-stage biopharmaceutical company, completed a $21 million Series A financing round led by Avalon BioVentures, with participation from Correlation Ventures, Alexandria Venture Investments, and other investors. The funding will accelerate the late-stage clinical development of AERO-007, a nebulized LABA/LAMA combination therapy for COPD, enabling a Phase 2b dose-optimization study and NDA-enabling development. The therapy addresses an unmet need in COPD treatment, as many patients struggle with inhaler coordination or fail to receive full therapeutic benefit from standard handheld inhalers.SecSEC FORM DAeroRx Therapeutics, Inc., a Delaware corporation headquartered in La Jolla, California, filed a Form D notice with the SEC for an exempt offering of equity securities under Rule 506(b) and 506(c), with a first sale reported on September 25, 2025. The total offering amount is $20,751,992 USD, of which $10,376,003 has already been sold to 17 investors, leaving approximately $10.4 million remaining. The filing discloses no sales commissions or finder's fees, and no proceeds are designated for payments to executive officers, directors, or promoters.FinSMEsAeroRx Therapeutics Raises $21M in Series A FinancingAeroRx Therapeutics raised $21M in Series A funding led by Avalon BioVentures. The company will use the funds for late-stage clinical development of its lead candidate, inhaled AERO-007, a nebulized LABA/LAMA combination for COPD. A second program, AERO-111, is in development as a triple therapy.BioSpaceAeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical DevelopmentAeroRx Therapeutics announced a $21 million Series A financing to fund late-stage clinical development of inhaled AERO-007, a nebulized LABA/LAMA therapy for COPD. Phase 2a trial data showed the drug was well tolerated and provided sustained bronchodilation over 24 hours, supporting further clinical testing.Business Wire BlogAeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical DevelopmentAeroRx Therapeutics closed a $21 million Series A financing round led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments, to advance its lead candidate AERO-007 into late-stage clinical development for COPD treatment. AERO-007 is the first nebulized LABA/LAMA combination therapy in development as a first-line maintenance therapy for COPD, with positive Phase 2a data demonstrating sustained 24-hour bronchodilation with once-daily dosing. The funding will support a Phase 2b dose-optimization study and preparation for NDA-enabling development.VC News DailyAeroRx Therapeutics Secures $21M Series AAeroRx Therapeutics, a clinical-stage biopharmaceutical company based in La Jolla, California, announced the closing of a $21 million Series A financing round led by Avalon BioVentures with participation from Correlation Ventures, Alexandria Venture Investments, and other investors. The proceeds will support late-stage clinical development of AERO-007, the company's lead candidate and the first nebulized LABA/LAMA fixed-dose combination drug in clinical development as a potential first-line maintenance therapy for chronic obstructive pulmonary disease (COPD). The company is also developing AERO-111 as a potential nebulized LABA/LAMA/ICS triple therapy for patients requiring escalated treatment.